Vaccine

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of…

3 weeks ago
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses MeetingGenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene…

3 weeks ago
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19,…

3 weeks ago
Piramal Pharma Limited Announces Results for Q4 and FY2025Piramal Pharma Limited Announces Results for Q4 and FY2025

Piramal Pharma Limited Announces Results for Q4 and FY2025

MUMBAI, India, May 14, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness…

4 weeks ago
IO Biotech Reports First Quarter 2025 Financial Results and Business HighlightsIO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still…

4 weeks ago
Rapid Dose Announces Proposed Debt SettlementRapid Dose Announces Proposed Debt Settlement

Rapid Dose Announces Proposed Debt Settlement

Burlington, Ontario--(Newsfile Corp. - May 9, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces that…

1 month ago
Anivive’s Dr. Edward Robb Presents Innovative Valley Fever Vaccine Research at World Vaccine Congress 2025Anivive’s Dr. Edward Robb Presents Innovative Valley Fever Vaccine Research at World Vaccine Congress 2025

Anivive’s Dr. Edward Robb Presents Innovative Valley Fever Vaccine Research at World Vaccine Congress 2025

WASHINGTON, May 9, 2025 /PRNewswire/ -- Dr. Edward Robb, Chief Strategy Officer, Anivive Lifesciences presented their pioneering research update on…

1 month ago
Ocugen Provides Business Update with First Quarter 2025 Financial ResultsOcugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing…

1 month ago
Dario’s Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk PopulationsDario’s Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

Dario’s Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes NEW…

1 month ago